ArticleGenes & development2022
Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2 mutant meningiomas in mice.
Article in Genes & development, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Meningioma animal models: a systematic review and meta-analysis.Journal of translational medicine · 2023Pooled it
- Visualizing genomic characteristics across an RNA-Seq based reference landscape of normal and neoplastic brain.Scientific reports · 2023Pooled it
- Distinct molecular subgroups in pediatric and young-onset meningiomas require age-adapted risk stratification.Nature communications · 2026Article
- A proteogenomic RNA processing mechanism drives sex differences in meningioma.Research square · 2026Article
- Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant lines.bioRxiv : the preprint server for biology · 2026Article
- Multidimensional Regulatory Network ofOncology research · 2026Review
- C-terminal fusion partner activity contributes to the oncogenic functions of YAP1::TFE3.Scientific reports · 2025Article
- Advancements of anticancer agents by targeting the Hippo signalling pathway: biological activity, selectivity, docking analysis, and structure-activity relationship.Molecular diversity · 2025Review
- Article
- Clinical Implementation of Expanded Solid Tumor Fusion Detection With Whole-Transcriptome Sequencing at an Academic Cancer Center.JCO precision oncology · 2025Article
- Article
- C-terminal fusion partner activity contributes to the oncogenic functions of YAP1::TFE3.bioRxiv : the preprint server for biology · 2025Article
- Anaplastic meningioma in a 6-year-old with somatic YAP1::MAML2 fusion and multiple endocrine neoplasia type 4 (MEN4) syndrome.Cancer genetics · 2025Article
- TEAD1::NCOA2 fusion driver in primary central nervous system malignancy: case report.Acta neuropathologica · 2025Article
- Lead exposure promotes NF2-wildtype meningioma cell proliferation through the Merlin-Hippo signaling pathway.Environmental health and preventive medicine · 2025Article
- Context-specific targeting of focal adhesion kinase in brain tumors: lessons from glioblastoma and neurofibromatosis type 2-mutant meningioma.Frontiers in oncology · 2025Review
- Hansemann's anaplastic theory of cancer after 135 years.Frontiers in epigenetics and epigenomics · 2025Article
- Seq-ing answers: exploring meningioma biology utilizing bulk RNA-seq-based reference landscapes.Frontiers in oncology · 2025Review
- The YAP1-MAML2 fusion drives tumorigenesis and sustains tumor growth.Molecular therapy. Oncology · 2024Article
- Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.Disease models & mechanisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
YAP1 is a transcriptional coactivator regulated by the Hippo signaling pathway, including NF2. Meningiomas are the most common primary brain tumors; a large percentage exhibit heterozygous loss of chromosome 22 (harboring the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.